BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

AMPH upcoming catalysts

Amphastar Pharmaceuticals, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 2 FDA event(s). Subscribe to AMPH (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-06-16FDA approvalapprovedAMPHASTAR PHARMS INC AMPHREXTOVYApproved 2026-06-16: REXTOVY (NDA208969 SUPPL2)
2026-02-26Complete response lettercomplete responseAmphastar Pharmaceuticals, Inc. AMPHWe also acknowledge receipt of your amendment dated as SP which was not reviewed for this actionCRL 2026-02-26: Amphastar Pharmaceuticals, Inc. BLA 761403 (We also acknowledge receipt of your amendment dated as SP which was not reviewed for this action)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-06-22P2/P3Amphastar Pharmaceuticals, Inc. AMPHNCT07560150 Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NoPharmacokinetics; Pharmacodynamics; Insulin Aspartcompleted62

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.